Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Drugs

16-04-2024 | Ruxolitinib | Adis Drug Evaluation

Ruxolitinib Cream 1.5%: A Review in Non-Segmental Vitiligo

Author: Connie Kang

Published in: Drugs

Login to get access

Abstract

Topical ruxolitinib 1.5% cream (Opzelura®), a Janus kinase (JAK) inhibitor, is the first treatment to be approved in several countries for use in patients aged ≥ 12 years with non-segmental vitiligo. In the identical phase III TRuE-V1 and TRuE-V2 trials, significantly more ruxolitinib cream recipients were able to achieve statistically significant and clinically meaningful facial and total body repigmentation, as well as reductions in vitiligo noticeability, compared with vehicle recipients. Efficacy was sustained in longer-term analyses to week 104 of treatment. Ruxolitinib 1.5% cream was generally tolerable in these trials; the most common treatment-related adverse events were acne, pruritus and exfoliation, all at the application site. As with orally administered JAK inhibitors, topical ruxolitinib carries boxed warnings in the USA for serious infections, mortality, malignancy, major adverse cardiovascular events (MACE) and thrombosis, although the incidences were low with topical application. Thus, topical ruxolitinib 1.5% cream is an effective and generally tolerable treatment option for patients aged ≥ 12 years with non-segmental vitiligo.
Appendix
Available only for authorised users
Literature
1.
Böhm M, Schunter JA, Fritz K, et al. S1 guideline: diagnosis and therapy of vitiligo. J Dtsch Dermatol Ges. 2022;20(3):365–78.PubMed
2.
van Geel N, Speeckaert R, Taïeb A, et al. Worldwide expert recommendations for the diagnosis and management of vitiligo: position statement from the International Vitiligo Task Force part 1: towards a new management algorithm. J Eur Acad Dermatol Venereol. 2023;37(11):2173–84.CrossRefPubMed
3.
AL-smadi K, Imran M, Leite-Silva VR, et al. Vitiligo: a review of aetiology, pathogenesis, treatment, and psychosocial impact. Cosmetics. 2023;10(3):84.CrossRef
4.
Bibeau K, Ezzedine K, Harris JE, et al. Mental health and psychosocial quality-of-life burden among patients with vitiligo: findings from the global VALIANT study. JAMA Dermatol. 2023;159(10):1124–8.CrossRefPubMedPubMedCentral
5.
Seneschal J, Speeckaert R, Taïeb A, et al. Worldwide expert recommendations for the diagnosis and management of vitiligo: position statement from the international Vitiligo Task Force part 2: specific treatment recommendations. J Eur Dermatol Venerol. 2023;37(11):2185–95.CrossRef
6.
Martins C, Migayron L, Drullion C, et al. Vitiligo skin T cells are prone to produce type 1 and type 2 cytokines to induce melanocyte dysfunction and epidermal inflammatory response through Jak signaling. J Investig Dermatol. 2022;142(4):1194-205.e7.CrossRefPubMed
7.
8.
9.
10.
Hoy SM. Ruxolitinib cream 1.5%: a review in mild to moderate atopic dermatitis. Am J Clin Dermatol. 2023;24(1):143–51.CrossRefPubMed
11.
Fridman JS, Scherle PA, Collins R, et al. Preclinical evaluation of local JAK1 and JAK2 inhibition in cutaneous inflammation. J Investig Dermatol. 2011;131(9):1838–44.CrossRefPubMed
12.
Persaud I, Diamond S, Pan R, et al. Plasma pharmacokinetics and distribution of ruxolitinib into skin following oral and topical administration in minipigs. Int J Pharm. 2020;590(119889):1–6.
13.
Rothstein B, Joshipura D, Saraiya A, et al. Treatment of vitiligo with the topical Janus kinase inhibitor ruxolitinib. J Am Acad Dermatol. 2017;76(6):1054-60.e1.CrossRefPubMed
14.
Rosmarin D, Pandya AG, Lebwohl M, et al. Ruxolitinib cream for treatment of vitiligo: a randomised, controlled, phase 2 trial. Lancet. 2020;396(10244):110–20.CrossRefPubMed
15.
Harris JE, Pandya AG, Lebwohl M, et al. Safety and efficacy of ruxolitinib cream for the treatment of vitiligo: 156-week data from a phase II study [abstract no. P96 plus poster]. Br J Dermatol. 2022;187(Suppl. 1):80–1.
16.
Rosmarin D, Passeron T, Pandya AG, et al. Two phase 3, randomized, controlled trials of ruxolitinib cream for vitiligo. N Engl J Med. 2022;387(16):1445–55.CrossRefPubMed
17.
Rosmarin D, Ezzedine K, Desai S. Efficacy and safety of ruxolitinib cream for the treatment of vitiligo by patient demographics and baseline clinical characteristics: pooled subgroup analysis from two randomized phase 3 studies [abstract no. 35187 plus poster]. J Am Acad Dermatol. 2022;87(3):AB50.CrossRef
18.
Rosmarin D, Ezzedine K, Md P, et al. Efficacy and safety of ruxolitinib cream for the treatment of vitiligo: week 24 pooled analysis of the TRuE-V phase 3 studies [abstract no. 34789 plus poster]. J Am Acad Dermatol. 2022;87(3):AB51.CrossRef
19.
Ezzedine K, van Geel N, Butler K, et al. Subgroup analysis of quality of life and treatment satisfaction by disease duration and use of prior treatment: pooled results from two randomized phase 3 studies of ruxolitinib cream for the treatment of vitiligo [abstract no. CO108 plus poster]. Value Health. 2022;25(7 Suppl.):S324.CrossRef
20.
Pandya AG, van Geel N, Butler K, et al. Subgroup analysis of quality of life and treatment satisfaction by baseline patient characteristics: pooled results from two randomized phase 3 studies of ruxolitinib cream for the treatment of vitiligo [abstract no. CO96 plus poster]. Value Health. 2022;25(7 Suppl.):S321–2.CrossRef
21.
Harris JE, Rosmarin D, Seneschal J, et al. Facial vitiligo area scoring index response maintenance or shift during 52 weeks of ruxolitinib cream treatment for vitiligo: pooled analysis of the TRuE-V phase 3 studies [abstract no. 43912 plus poster]. In: American Academy of Dermatology (AAD) Annual Meeting. 2023.
22.
Rosmarin D, Harris JE, Wolkerstorfer A, et al. Total vitiligo area scoring index response maintenance or shift during 52 weeks of ruxolitinib cream treatment for vitiligo: pooled analysis of the TRuE-V phase 3 studies [abstract no. 43938 plus poster]. In: American Academy of Dermatology (AAD) Annual Meeting. 2023.
23.
Ezzedine K, Passeron T, Rosmarin D, et al. Vitiligo noticeability scale score maintenance or shift during 52 weeks of ruxolitinib cream treatment for vitiligo: pooled analysis of the TRuE-V phase 3 studies [abstract no. 43959 plus poster]. In: American Academy of Dermatology (AAD) Annual Meeting. 2023.
24.
Seneschal J, Wolkerstorfer A, Desai SR, et al. Efficacy and safety of ruxolitinib cream for the treatment of vitiligo by patient demographics and baseline clinical characteristics: week 52 pooled subgroup analysis from two randomized phase 3 studies [abstract no. 555 plus poster P1383]. In: 31st European Academy of Dermatology and Venereology (EADV) Congress. 2022.
25.
Seneschal J, Grimes P, Desai SR, et al. Efficacy and safety of ruxolitinib cream in adolescent patients with vitiligo: pooled analysis of the 52-week TRuE-V phase 3 studies. In: Society for Pediatric Dermatology 47th Annual Meeting. 2022.
26.
Seneschal J, Wolkerstorfer A, Ezzedine K, et al. Efficacy and safety of ruxolitinib cream through week 104 in patients with vitiligo: subgroup analysis of the TRuE-V long-term extension phase 3 study [abstract no. 927 plus poster P2229]. In: 32nd European Academy of Dermatology and Venereology (EADV) Congress. 2023.
27.
Rosmarin D, Sebastian M, Amster M, et al. Facial and total vitiligo area scoring index response shift during 104 weeks of ruxolitinib cream treatment for vitiligo: results from the open-label arm of the TRuEV long-term extension phase 3 study [abstract plus presentation]. In: American Academy of Dermatology (AAD) Annual Meeting. 2023.
28.
Pandya AG, Ezzedine K, Rosmarin D, et al. Treatment-emergent adverse events of interest for janus kinase inhibitors: pooled analysis of the 52-week TRuE-V phase 3 studies of ruxolitinib cream treatment for vitiligo [abstract no. 43978 plus poster]. In: American Academy of Dermatology (AAD) Annual Meeting. 2023.
29.
30.
Eleftheriadou V, Atkar R, Batchelor J, et al. British Association of Dermatologists guidelines for the management of people with vitiligo 2021. Br J Dermatol. 2021;186(1):18–29.CrossRefPubMed
31.
Kitchen H, Wyrwich KW, Carmichael C, et al. Meaningful changes in what matters to individuals with vitiligo: content validity and meaningful change thresholds of the Vitiligo Area Scoring Index (VASI). Dermatol Ther (Heidelb). 2022;12(7):1623–37.CrossRefPubMedPubMedCentral
32.
Ehsan M, Rehman AU, Ayyan M, et al. Efficacy and safety of topical ruxolitinib cream for the treatment of vitiligo: a systematic review and meta-analysis of randomized controlled trials. J Cosmet Dermatol. 2023;31(1):350–3.CrossRef
Metadata
Title
Ruxolitinib Cream 1.5%: A Review in Non-Segmental Vitiligo
Author
Connie Kang
Publication date
16-04-2024
Publisher
Springer International Publishing
Published in
Drugs
Print ISSN: 0012-6667
Electronic ISSN: 1179-1950
DOI
https://doi.org/10.1007/s40265-024-02027-2